EUVIMEDEUVIMED entdecken
Open Access

Differences and Common Ground in 177 Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers

Andrea Farolfi, Wesley R Armstrong, Loic Djaileb, Andrei Gafita, Masatoshi Hotta, Martin Allen-Auerbach, Lena M Unterrainer, Wolfgang P Fendler, Matthew Rettig, Matthias Eiber, Michael S Hofman, Boris Hadaschik und 4 weitere

Journal of Nuclear Medicine · 2024-03 · 65 (3) · 438-445

DOI: 10.2967/jnumed.123.266391 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 18.01.2024. Verfasst von Andrea Farolfi und 15 weiteren Autor:innen. Beteiligte Einrichtung: Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California. Hauptthemen laut MEDLINE: Precision Medicine, Positron Emission Tomography Computed Tomography. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

177Lu-labeled prostate-specific membrane antigen (PSMA) radioligand therapy effectively treats metastatic castration-resistant prostate cancer. Patients requiring treatment, and consequently the number of theranostic centers, are expected to increase significantly after Food and Drug Administration and European Medicines Agency approval. This requires standardization or harmonization among theranostic centers. The aim of this study was to assess operational differences and similarities among 177Lu-PSMA treatment centers.

Methods

A questionnaire comprising 62 items, designed by a core team of 5 physicians and externally reviewed by international experts, was developed. Study participants were asked to provide answers about their center, patient selection, radiopharmaceuticals, clinical assessment before and after 177Lu-PSMA treatments, laboratory values, treatment discontinuation, posttreatment imaging, and general information. An invitation e-mail to participate in the study was sent in June 2022. Duplicates were removed to allow for only one valid response per center.

Results

Ninety-five of 211 (45%) contacted centers completed the questionnaire. Most participating centers were in Europe (51%), followed by America (22%) and Asia (22%). During the 12 mo before this study, a total of 5,906 patients received 177Lu-PSMA therapy at the 95 participating centers. Most of these patients were treated in Europe (2,840/5,906; 48%), followed by Asia (1,313/5,906; 22%) and Oceania (1,225/5,906; 21%). PSMA PET eligibility for 177Lu-PSMA was determined most frequently using 68Ga-PSMA-11 (77%). Additional pretherapy imaging included 18F-FDG PET/CT, CT, renal scintigraphy, and bone scintigraphy at 41 (49%), 27 (32%), 25 (30%), and 13 (15%), respectively, of the 84 centers for clinical standard of care, compassionate care, or local research protocols and 11 (26%), 25 (60%), 9 (21%), and 28 (67%), respectively, of the 42 centers for industry-sponsored trials. PSMA PET eligibility criteria included subjective qualitative assessment of PSMA positivity at 33% of centers, VISION criteria at 23%, and TheraP criteria at 13%. The mean standard injected activity per cycle was 7.3 GBq (range, 5.5-11.1 GBq). Sixty-two (65%) centers applied standardized response assessment criteria, and PSMA PET Progression Criteria were the most applied (37%).

Conclusion

Results from this international survey revealed interinstitutional differences in several aspects of 177Lu-PSMA radionuclide therapy, including patient selection, administered activity, and the response assessment strategy. Standardization or harmonization of protocols and dedicated training are desirable in anticipation of increasing numbers of patients and theranostic centers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precision MedicinePositron Emission Tomography Computed TomographyUnited StatesMaleHumansEuropeGallium Radioisotopes

Stichwörter der Autor:innen

177Lu-PSMAPET/CTprostate cancerradionuclide therapysurveytheranostic

Substanzen

PSMA-11Gallium Radioisotopes

Autor:innen und Institutionen

  • Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
  • Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • LRB, Nuclear Medicine Department, CHU Grenoble Alpes, University of Grenoble Alpes, INSERM, Grenoble, France.
  • Division of Nuclear Medicine and Molecular Imaging, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Department of Nuclear Medicine, Ludwig-Maximilian University, Munich, Germany.
  • Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium-University Hospital Essen, Essen, Germany.

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS

Zitieren

APA

Farolfi, A., Armstrong, W. R., Djaileb, L., Gafita, A., Hotta, M., Allen-Auerbach, M., Unterrainer, L. M., Fendler, W. P., Rettig, M., Eiber, M., Hofman, M. S., Hadaschik, B., Herrmann, K., Czernin, J., Calais, J., & Benz, M. R. (2024). Differences and Common Ground in 177 Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers. Journal of Nuclear Medicine, 65(3), 438-445. https://doi.org/10.2967/jnumed.123.266391

Vancouver

Farolfi A, Armstrong WR, Djaileb L, Gafita A, Hotta M, Allen-Auerbach M, et al. Differences and Common Ground in 177 Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers. Journal of Nuclear Medicine. 2024;65(3):438-445. doi:10.2967/jnumed.123.266391

BibTeX
@article{Farolfi2024,
  author = {Farolfi, Andrea and Armstrong, Wesley R and Djaileb, Loic and Gafita, Andrei and Hotta, Masatoshi and Allen-Auerbach, Martin and Unterrainer, Lena M and Fendler, Wolfgang P and Rettig, Matthew and Eiber, Matthias and Hofman, Michael S and Hadaschik, Boris and Herrmann, Ken and Czernin, Johannes and Calais, Jeremie and Benz, Matthias R},
  title = {Differences and Common Ground in 177 Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers},
  journal = {Journal of Nuclear Medicine},
  year = {2024},
  volume = {65},
  number = {3},
  pages = {438--445},
  doi = {10.2967/jnumed.123.266391}
}
Kostenlos starten →